162 related articles for article (PubMed ID: 30570865)
1. Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.
Duan J; Yang Z; Liu D; Shi Y
J BUON; 2018; 23(5):1402-1406. PubMed ID: 30570865
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
4. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Zhang L; Zhang Y; Li N; Xu F; Pan ZK; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1455-8. PubMed ID: 15566656
[TBL] [Abstract][Full Text] [Related]
5. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Quan R; Huang J; Chen N; Fang W; Hu Z; Zhan J; Zhou T; Zhang L; Zhang H
Tumour Biol; 2016 Aug; 37(8):11479-84. PubMed ID: 27012553
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
Mok TS; Hsia TC; Tsai CM; Tsang K; Chang GC; Chang JW; Sirisinha T; Sriuranpong V; Thongprasert S; Chua DT; Moore N; Manegold C
Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():4-12. PubMed ID: 21585703
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
[TBL] [Abstract][Full Text] [Related]
9. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Zhao WY; Chen DY
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):775-9. PubMed ID: 23291073
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Zhang YM; Li YQ; Liu ZH; Liao XL; Liang R; Lin Y; Yuan CL; Liao SN; Liang CY; Li Q; Li LQ
Asian Pac J Cancer Prev; 2014; 15(8):3447-50. PubMed ID: 24870737
[TBL] [Abstract][Full Text] [Related]
11. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G
Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Zhao T; Jin Y; Mao G; Wei Y; Wu G; Ye X; Zhou Y; Yuan G; Gao L; Hong Y; Chen Y; Hong C; Zhou H; Su D; Qin Z; Lu L
Medicine (Baltimore); 2016 Dec; 95(52):e5748. PubMed ID: 28033287
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Reck M; von Pawel J; Zatloukal P; Ramlau R; Gorbounova V; Hirsh V; Leighl N; Mezger J; Archer V; Moore N; Manegold C
J Clin Oncol; 2009 Mar; 27(8):1227-34. PubMed ID: 19188680
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
[TBL] [Abstract][Full Text] [Related]
17. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Mylonakis N; Athanasiou A; Ziras N; Angel J; Rapti A; Lampaki S; Politis N; Karanikas C; Kosmas C
Lung Cancer; 2010 May; 68(2):240-7. PubMed ID: 19628292
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Thomas M; Fischer J; Andreas S; Kortsik C; Grah C; Serke M; von Eiff M; Witt C; Kollmeier J; Müller E; Schenk M; Schröder M; Villalobos M; Reinmuth N; Penzel R; Schnabel P; Acker T; Reuss A; Wolf M;
Eur Respir J; 2015 Jul; 46(1):219-29. PubMed ID: 25792638
[TBL] [Abstract][Full Text] [Related]
20. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Patil PD; Shapiro M; Hashemi Sadraei N; Pennell NA
Oncologist; 2019 Apr; 24(4):457-e126. PubMed ID: 30602615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
